Overexpression of wild type RRAS2, without oncogenic mutations, drives chronic lymphocytic leukemia

Alejandro M Hortal
Universidad Autónoma de Madrid
January 1, 2022
Mol Cancer
https://pubmed.ncbi.nlm.nih.gov/35120522

This article is currently being updated. View its version on PubMed.

https://pubmed.ncbi.nlm.nih.gov/35120522

Research summary

This study investigates the role of wild-type RRAS2 overexpression in the development of chronic lymphocytic leukemia (CLL). Researchers generated a conditional Knockin mouse model with human RRAS2 inserted into the Rosa26 locus, controlled by a loxP-flanked STOP cassette and an IRES-EGFP reporter. Upon Cre-mediated recombination, RRAS2 is overexpressed in B cells, leading to the development of CLL characterized by CD5+IgM+ B cell expansion, splenomegaly, and reduced survival. The model mirrors human CLL features and is valuable for preclinical testing of therapies.

Key outcome of the study

Overexpression of wild-type RRAS2 in B cells induces CLL-like disease in mice, demonstrating its oncogenic potential without activating mutations and providing a model for therapeutic research.

Model

Conditional Knockin mouse model with human RRAS2 inserted into the Rosa26 locus, featuring a loxP-flanked STOP cassette and an IRES-EGFP reporter; Cre recombinase under the mb1 promoter ensures B cell-specific expression.

TARGET:
RRAS2
Synonyms:
TC21

Keywords

Chronic lymphocytic leukemia, B cell malignancy, Oncogene overexpression, Preclinical model

Technical specifications

Knockin model, Rosa26 locus, loxP-flanked STOP cassette, IRES-EGFP reporter, B cell-specific Cre expression

Related products

Catalogue product

No items found.

Customized product

No items found.

Catalogue product

No items found.
Scientific excellence

From model design to experimental results
Featured in 600+ scientific articles

Collaborative approach

Collaboration with 17 Top Pharmas,
170+ Biotechs and 380+ Academic Institutions

Robust validation data on catalog models

Generated with biopharma partners and in-house

Innovative technologies

and guaranteed freedom to operate

Easy access to models

Models with certified health status from professional breeders in US and Europe